HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

Johannes F. Scheid, Joshua A. Horwitz, Yotam Bar-On, Edward F. Kreider, Ching Lan Lu, Julio C C Lorenzi, Anna Feldmann, Malte Braunschweig, Lilian Nogueira, Thiago Oliveira, Irina Shimeliovich, Roshni Patel, Leah Burke, Yehuda Z. Cohen, Sonya Hadrigan, Allison Settler, Maggi Witmer-Pack, Anthony P. West,, Boris Juelg, Tibor KelerThomas Hawthorne, Barry S. Zingman, Roy M. Gulick, Nico Pfeifer, Gerald H. Learn, Michael S. Seaman, Pamela J. Bjorkman, Florian Klein, Sarah J. Schlesinger, Bruce D. Walker, Beatrice H. Hahn, Michel C. Nussenzweig, Marina Caskey

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

Interruption of combination antiretroviral therapy (ART) in HIV-1-infected individuals leads to rapid viral rebound. Here we report the results of a phase IIa open label clinical trial evaluating 3BNC117, a broad and potent neutralizing antibody (bNAb) against the CD4 binding site of HIV-1 Env1, in the setting of analytical treatment interruption (ATI) in 13 HIV-1-infected individuals. Participants with 3BNC117-sensitive virus outgrowth cultures were enrolled. Two or four 30 mg/kg infusions of 3BNC117, separated by 3 or 2 weeks, respectively, were generally well tolerated. The infusions were associated with a delay in viral rebound for 5-9 weeks after 2 infusions, and up to 19 weeks after 4 infusions, or an average of 6.7 and 9.9 weeks respectively, compared with 2.6 weeks for historical controls (p=

Original languageEnglish (US)
JournalNature
DOIs
StateAccepted/In press - 2016

Fingerprint

HIV Antibodies
HIV-1
Neutralizing Antibodies
Binding Sites
Clinical Trials
Viruses
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Scheid, J. F., Horwitz, J. A., Bar-On, Y., Kreider, E. F., Lu, C. L., Lorenzi, J. C. C., ... Caskey, M. (Accepted/In press). HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature. https://doi.org/10.1038/nature18929

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. / Scheid, Johannes F.; Horwitz, Joshua A.; Bar-On, Yotam; Kreider, Edward F.; Lu, Ching Lan; Lorenzi, Julio C C; Feldmann, Anna; Braunschweig, Malte; Nogueira, Lilian; Oliveira, Thiago; Shimeliovich, Irina; Patel, Roshni; Burke, Leah; Cohen, Yehuda Z.; Hadrigan, Sonya; Settler, Allison; Witmer-Pack, Maggi; West, Anthony P.; Juelg, Boris; Keler, Tibor; Hawthorne, Thomas; Zingman, Barry S.; Gulick, Roy M.; Pfeifer, Nico; Learn, Gerald H.; Seaman, Michael S.; Bjorkman, Pamela J.; Klein, Florian; Schlesinger, Sarah J.; Walker, Bruce D.; Hahn, Beatrice H.; Nussenzweig, Michel C.; Caskey, Marina.

In: Nature, 2016.

Research output: Contribution to journalArticle

Scheid, JF, Horwitz, JA, Bar-On, Y, Kreider, EF, Lu, CL, Lorenzi, JCC, Feldmann, A, Braunschweig, M, Nogueira, L, Oliveira, T, Shimeliovich, I, Patel, R, Burke, L, Cohen, YZ, Hadrigan, S, Settler, A, Witmer-Pack, M, West, AP, Juelg, B, Keler, T, Hawthorne, T, Zingman, BS, Gulick, RM, Pfeifer, N, Learn, GH, Seaman, MS, Bjorkman, PJ, Klein, F, Schlesinger, SJ, Walker, BD, Hahn, BH, Nussenzweig, MC & Caskey, M 2016, 'HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption', Nature. https://doi.org/10.1038/nature18929
Scheid, Johannes F. ; Horwitz, Joshua A. ; Bar-On, Yotam ; Kreider, Edward F. ; Lu, Ching Lan ; Lorenzi, Julio C C ; Feldmann, Anna ; Braunschweig, Malte ; Nogueira, Lilian ; Oliveira, Thiago ; Shimeliovich, Irina ; Patel, Roshni ; Burke, Leah ; Cohen, Yehuda Z. ; Hadrigan, Sonya ; Settler, Allison ; Witmer-Pack, Maggi ; West, Anthony P. ; Juelg, Boris ; Keler, Tibor ; Hawthorne, Thomas ; Zingman, Barry S. ; Gulick, Roy M. ; Pfeifer, Nico ; Learn, Gerald H. ; Seaman, Michael S. ; Bjorkman, Pamela J. ; Klein, Florian ; Schlesinger, Sarah J. ; Walker, Bruce D. ; Hahn, Beatrice H. ; Nussenzweig, Michel C. ; Caskey, Marina. / HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. In: Nature. 2016.
@article{19e29159765a45c0bfc9fc3eff3ef7cf,
title = "HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption",
abstract = "Interruption of combination antiretroviral therapy (ART) in HIV-1-infected individuals leads to rapid viral rebound. Here we report the results of a phase IIa open label clinical trial evaluating 3BNC117, a broad and potent neutralizing antibody (bNAb) against the CD4 binding site of HIV-1 Env1, in the setting of analytical treatment interruption (ATI) in 13 HIV-1-infected individuals. Participants with 3BNC117-sensitive virus outgrowth cultures were enrolled. Two or four 30 mg/kg infusions of 3BNC117, separated by 3 or 2 weeks, respectively, were generally well tolerated. The infusions were associated with a delay in viral rebound for 5-9 weeks after 2 infusions, and up to 19 weeks after 4 infusions, or an average of 6.7 and 9.9 weeks respectively, compared with 2.6 weeks for historical controls (p=",
author = "Scheid, {Johannes F.} and Horwitz, {Joshua A.} and Yotam Bar-On and Kreider, {Edward F.} and Lu, {Ching Lan} and Lorenzi, {Julio C C} and Anna Feldmann and Malte Braunschweig and Lilian Nogueira and Thiago Oliveira and Irina Shimeliovich and Roshni Patel and Leah Burke and Cohen, {Yehuda Z.} and Sonya Hadrigan and Allison Settler and Maggi Witmer-Pack and West,, {Anthony P.} and Boris Juelg and Tibor Keler and Thomas Hawthorne and Zingman, {Barry S.} and Gulick, {Roy M.} and Nico Pfeifer and Learn, {Gerald H.} and Seaman, {Michael S.} and Bjorkman, {Pamela J.} and Florian Klein and Schlesinger, {Sarah J.} and Walker, {Bruce D.} and Hahn, {Beatrice H.} and Nussenzweig, {Michel C.} and Marina Caskey",
year = "2016",
doi = "10.1038/nature18929",
language = "English (US)",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

AU - Scheid, Johannes F.

AU - Horwitz, Joshua A.

AU - Bar-On, Yotam

AU - Kreider, Edward F.

AU - Lu, Ching Lan

AU - Lorenzi, Julio C C

AU - Feldmann, Anna

AU - Braunschweig, Malte

AU - Nogueira, Lilian

AU - Oliveira, Thiago

AU - Shimeliovich, Irina

AU - Patel, Roshni

AU - Burke, Leah

AU - Cohen, Yehuda Z.

AU - Hadrigan, Sonya

AU - Settler, Allison

AU - Witmer-Pack, Maggi

AU - West,, Anthony P.

AU - Juelg, Boris

AU - Keler, Tibor

AU - Hawthorne, Thomas

AU - Zingman, Barry S.

AU - Gulick, Roy M.

AU - Pfeifer, Nico

AU - Learn, Gerald H.

AU - Seaman, Michael S.

AU - Bjorkman, Pamela J.

AU - Klein, Florian

AU - Schlesinger, Sarah J.

AU - Walker, Bruce D.

AU - Hahn, Beatrice H.

AU - Nussenzweig, Michel C.

AU - Caskey, Marina

PY - 2016

Y1 - 2016

N2 - Interruption of combination antiretroviral therapy (ART) in HIV-1-infected individuals leads to rapid viral rebound. Here we report the results of a phase IIa open label clinical trial evaluating 3BNC117, a broad and potent neutralizing antibody (bNAb) against the CD4 binding site of HIV-1 Env1, in the setting of analytical treatment interruption (ATI) in 13 HIV-1-infected individuals. Participants with 3BNC117-sensitive virus outgrowth cultures were enrolled. Two or four 30 mg/kg infusions of 3BNC117, separated by 3 or 2 weeks, respectively, were generally well tolerated. The infusions were associated with a delay in viral rebound for 5-9 weeks after 2 infusions, and up to 19 weeks after 4 infusions, or an average of 6.7 and 9.9 weeks respectively, compared with 2.6 weeks for historical controls (p=

AB - Interruption of combination antiretroviral therapy (ART) in HIV-1-infected individuals leads to rapid viral rebound. Here we report the results of a phase IIa open label clinical trial evaluating 3BNC117, a broad and potent neutralizing antibody (bNAb) against the CD4 binding site of HIV-1 Env1, in the setting of analytical treatment interruption (ATI) in 13 HIV-1-infected individuals. Participants with 3BNC117-sensitive virus outgrowth cultures were enrolled. Two or four 30 mg/kg infusions of 3BNC117, separated by 3 or 2 weeks, respectively, were generally well tolerated. The infusions were associated with a delay in viral rebound for 5-9 weeks after 2 infusions, and up to 19 weeks after 4 infusions, or an average of 6.7 and 9.9 weeks respectively, compared with 2.6 weeks for historical controls (p=

UR - http://www.scopus.com/inward/record.url?scp=84976406858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976406858&partnerID=8YFLogxK

U2 - 10.1038/nature18929

DO - 10.1038/nature18929

M3 - Article

C2 - 27338952

AN - SCOPUS:84976406858

JO - Nature

JF - Nature

SN - 0028-0836

ER -